D9060
CAS Number
405169-16-6Grade
Highly PurifiedMolecular Formula
C21H21FN6OMolecular Weight
392.43EU Commodity Code
38220090Shipping Temp
Blue IceStorage Temp
-20°CDovitinib, Free Base (4-Amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone) (CHIR-258, TKI-258)
Dovitinib is a small-molecule multi-targeted receptor tyrosine kinase inhibitor. Dovitinib inhibited Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150nM and 90nM, respectively. The phosphorylation of each fusion gene, ERK, and STAT5 was inhibited as well at the same time. Dovitinib treatment also inhibited proliferation and survival of the FGFR1OP2-FGFR1-positive KG1 and KG1A cell lines and resulted in cell apoptosis. Furthermore, Dovitinib significantly inhibited the survival of primary cells from 8p11 myeloproliferative syndrome (EMS) patients dose-dependently.
Solubility
Soluble in DMSO
Elemental Analysis
Calculated C: 64.27% H: 5.39% F: 4.84% N: 21.42%
Storage and Stability
May be stored at RT for short-term only. Long-term storage is recommended at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Form
Supplied as a yellow to green crystalline powder
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. Chase, A., et al. Blood 110: 3729-3734 (2007). 2. Trudel, S., et al., Blood 105: 2941-2948 (2005). 3. Lee, S.H., et al., Clin. Cancer Res. 11: 3633-3641 (2005). 4. Lopes de Menezes, D.E., et al., Clin. Cancer Res. 11: 5281-5291 (2005). 5. Xin, X., et al., Clin. Cancer Res. 12: 4908-4915 (2006).USBio References
No references available